Storms may be on the horizon for Intercept after Ocaliva received a complete response letter from the FDA in primary biliary cholangitis. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
